MaSTherCell Global Announces Promotions of Darren Head as Chief Executive Officer and Dr. Denis Bedoret as President
GREENWICH, CT and CHARLEROI, BELGIUM - January 25, 2019 - Great Point Partners, LLC (“Great Point”), a Greenwich-based private investment firm focused on the health care industry and MaSTherCell Global, Inc. (“MaSTherCell Global”), a portfolio company and strategic partner of Great Point, today announced executive promotions at MaSTherCell Global effective January 1, 2019.
Great Point Partners-Backed Strategic Partner MaSTherCell Global Announces Achievement of First Milestone Funding and Expansion with New Facility in Houston, Texas
GREENWICH, CT and HOUSTON, TX - January 25, 2019 - Great Point Partners, LLC (“Great Point”), a Greenwich-based private investment firm focused on the health care industry, announces today that its portfolio company and strategic partner MaSTherCell Global, Inc. (“MaSTherCell Global”) achieved its first financial milestone targets and as a result Great Point has funded $6.6 million of growth equity to the company’s balance sheet.
MaSTherCell expands production by doubling its capacity
GOSSELIES, BELGIUM – November 30, 2018 – MaSTherCell S.A. a subsidiary of Orgenesis Inc. (NASDAQ: ORGS) through Masthercell Global Inc., a cell therapy-dedicated Contract Development and Manufacturing Organization (CDMO) launched a new production wing of 600 m² at its Belgium site in the presence of the Minister-President of Wallonia, Willy Borsus. Masthercell is also backed by Great Point Partners, LLC (“GPP”), a leading healthcare investment firm based in Greenwich, Connecticut.
Iovance Biotherapeutics and MaSTherCell Announce New Manufacturing Services Agreement in Europe
SAN CARLOS, CA and GOSSELIES, BELGIUM – October 18, 2018 – Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor infiltrating lymphocyte (TIL) technology, and MaSTherCell S.A. a subsidiary of Orgenesis Inc. (NASDAQ: ORGS) through Masthercell Global Inc., a cell therapy-dedicated Contract Development and Manufacturing Organization (CDMO) today announced that the two companies have entered into a new three-year Manufacturing Services Agreement. MaSTherCell will manufacture TIL for Iovance’s European late-stage clinical trials in its commercial-ready cGMP manufacturing suites.
Kangstem Biotech selects MaSTherCell for GMP manufacturing of FURESTEM-ADİ in Europe
Seoul, Korea and Gosselies, Belgium, October 1, 2018 – Kangstem Biotech, a biotechnology company specializing in developing cell therapies using mesenchymal stem cells derived from human umbilical cord blood, today announces the selection of MaSTherCell as its contract manufacturing partner for its European clinical trial of FURESTEM-AD.
MaSTherCell announces planned investment for MaSTherCell Global of up to $25 Million
MaSTherCell announces planned investment for MaSTherCell Global of up to $25 Million to develop its global services through a strategic partnership between Orgenesis and Great Point Partners
MaSTherCell Global will beneficiate from a USD 25 million funding from a partnership between Orgenesis Inc. and Great Point Partners (GPP), a leading health care investment firm based in Greenwich, Connecticut, in order to finance, strengthen and expand MaSTherCell Global’s activities.